Table 1. Baseline Characteristics by Statusa.
Characteristic | Participated in Lymphedema Substudy (n = 486) | Not Included in This Analysis (n = 215) | P Value |
---|---|---|---|
Age, mean (SD), y | 50.1 (10.8) | 51.1 (11.4) | .25 |
Race | |||
White | 391 (80.4) | 174 (80.9) | .15 |
Black | 71 (14.6) | 28 (13.0) | |
Asian | 15 (3.1) | 4 (1.9) | |
Native American | 0 | 2 (0.9) | |
>1 Race | 0 | 1 (0.5) | |
Unknown or not reported | 9 (1.8) | 6 (2.8) | |
Ethnicity | |||
Hispanic or Latino | 42 (8.6) | 24 (11.2) | .40 |
Not Hispanic or Latino | 418 (86.0) | 183 (85.1) | |
Unknown or not reported | 26 (5.4) | 8 (3.7) | |
Baseline performance status | |||
0 | 385 (79.2) | 177 (82.3) | .59 |
1 | 100 (20.6) | 38 (17.7) | |
2 | 1 (0.2) | 0 | |
Smoking status | |||
Current | 56 (11.5) | 29 (13.5) | .16 |
Never | 342 (70.4) | 139 (64.6) | |
Past | 74 (15.2) | 34 (15.8) | |
Unknown | 14 (2.9) | 13 (6.0) | |
Diabetes | |||
No | 443 (91.2) | 201 (93.5) | .30 |
Yes | 43 (8.8) | 14 (6.5) | |
Peripheral vascular disease | |||
No | 484 (99.6) | 213 (99.1) | .59 |
Yes | 2 (0.4) | 2 (0.9) | |
Arthritis | |||
No | 447 (92.0) | 206 (95.8) | .06 |
Yes | 39 (8.0) | 9 (4.2) | |
Cardiac disease | |||
No | 356 (73.2) | 166 (77.2) | .27 |
Yes | 130 (26.8) | 49 (22.8) | |
Neoadjuvant chemotherapy regimen | |||
Anthracycline-containing regimen | 23 (4.7) | 21 (9.8) | .08 |
Taxane-containing regimen | 84 (17.3) | 38 (17.7) | |
Anthracycline- and taxane-containing regimen | 371 (76.3) | 152 (70.7) | |
Other | 8 (1.6) | 4 (1.9) | |
BMI categoryb | |||
<25 | 137 (28.3) | 59 (27.4) | .06 |
25-29.99 | 127 (26.2) | 78 (36.3) | |
30-34.99 | 118 (24.4) | 40 (18.6) | |
35-39.99 | 62 (12.8) | 26 (12.1) | |
≥40 | 40 (8.3) | 12 (5.6) | |
Estrogen receptor status | |||
Positive | 299 (61.5) | 128 (59.5) | .73 |
Negative | 186 (38.3) | 87 (40.5) | |
Not done | 1 (0.2) | 0 | |
Progesterone receptor status | |||
Positive | 253 (52.1) | 110 (51.2) | .76 |
Negative | 232 (47.7) | 104 (48.4) | |
Not done | 1 (0.2) | 1 (0.5) | |
Tumor biologyc | |||
HR positive/ERBB2 negative | 225 (46.6) | 92 (42.8) | .55 |
ERBB2 positive | 141 (29.2) | 71 (33.0) | |
Triple negative | 117 (24.2) | 52 (24.2) | |
T stage | |||
T0 | 6 (1.2) | 0 | .55 |
Tis | 1 (0.2) | 1 (0.5) | |
T1 | 61 (12.6) | 29 (13.5) | |
T2 | 270 (55.6) | 115 (53.5) | |
T3 | 127 (26.1) | 58 (27.0) | |
T4 | 21 (4.3) | 12 (5.6) | |
N stage | |||
N1 | 460 (94.6) | 203 (94.4) | .90 |
N2 | 26 (5.4) | 12 (5.6) | |
Radiotherapy receivedd | |||
Yes | 416 (87.0) | 175 (81.4) | .053 |
No | 62 (13.0) | 40 (18.6) |
Abbreviation: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared).
Data are presented as number (percentage) of patients unless otherwise indicated.
Data for 2 participants in the lymphedema substudy were unknown or not reported; thus, n = 484.
Data for 3 participants in the lymphedema substudy were unknown or not reported; thus, n = 483.
Data for 8 participants in the lymphedema substudy were unknown or not reported; thus, n = 478.